menu
    • menu
    [{"orgOrder":0,"company":"Osaka University","sponsor":"Bayer AG","pharmaFlowCategory":"DU","therapeuticArea":"Nephrology","country":"JAPAN","productType":"Miscellaneous","year":"2014","type":"Inapplicable","leadProduct":"Lanthanum Carbonate","moa":"Phosphate","graph1":"Nephrology","graph2":"Phase IV","graph3":"Osaka University","amount2":0,"highestDevelopmentShortName":"Ph IV","therapeuticAreaShortName":"Nephrology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Osaka University \/ Bayer AG","highestDevelopmentStatusID":"11","companyTruncated":"Osaka University \/ Bayer AG"},{"orgOrder":0,"company":"Bayer AG","sponsor":"SHIRE PLC","pharmaFlowCategory":"DU","therapeuticArea":"Nephrology","country":"GERMANY","productType":"Miscellaneous","year":"2010","type":"Inapplicable","leadProduct":"Lanthanum Carbonate","moa":"Phosphate","graph1":"Nephrology","graph2":"Phase III","graph3":"Bayer AG","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Nephrology","amount2New":0,"dosageForm":"Granules","sponsorNew":"Bayer AG \/ SHIRE PLC","highestDevelopmentStatusID":"10","companyTruncated":"Bayer AG \/ SHIRE PLC"},{"orgOrder":0,"company":"Bayer AG","sponsor":"SHIRE PLC","pharmaFlowCategory":"DU","therapeuticArea":"Nephrology","country":"GERMANY","productType":"Miscellaneous","year":"2010","type":"Inapplicable","leadProduct":"Lanthanum Carbonate","moa":"Phosphate","graph1":"Nephrology","graph2":"Phase III","graph3":"Bayer AG","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Nephrology","amount2New":0,"dosageForm":"Granules","sponsorNew":"Bayer AG \/ SHIRE PLC","highestDevelopmentStatusID":"10","companyTruncated":"Bayer AG \/ SHIRE PLC"},{"orgOrder":0,"company":"Bayer AG","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Nephrology","country":"GERMANY","productType":"Miscellaneous","year":"2012","type":"Inapplicable","leadProduct":"Lanthanum Carbonate","moa":"Phosphate","graph1":"Nephrology","graph2":"Phase III","graph3":"Bayer AG","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Nephrology","amount2New":0,"dosageForm":"Granules","sponsorNew":"Bayer AG \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Bayer AG \/ Undisclosed"},{"orgOrder":0,"company":"Bayer AG","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Nephrology","country":"GERMANY","productType":"Miscellaneous","year":"2012","type":"Inapplicable","leadProduct":"Lanthanum Carbonate","moa":"Phosphate","graph1":"Nephrology","graph2":"Phase III","graph3":"Bayer AG","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Nephrology","amount2New":0,"dosageForm":"Granules","sponsorNew":"Bayer AG \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Bayer AG \/ Undisclosed"},{"orgOrder":0,"company":"Bayer AG","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Nephrology","country":"GERMANY","productType":"Miscellaneous","year":"2010","type":"Inapplicable","leadProduct":"Lanthanum Carbonate","moa":"Phosphate","graph1":"Nephrology","graph2":"Phase III","graph3":"Bayer AG","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Nephrology","amount2New":0,"dosageForm":"Granules","sponsorNew":"Bayer AG \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Bayer AG \/ Undisclosed"},{"orgOrder":0,"company":"SHIRE PLC","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Nephrology","country":"IRELAND","productType":"Miscellaneous","year":"2010","type":"Inapplicable","leadProduct":"Lanthanum Carbonate","moa":"Phosphate","graph1":"Nephrology","graph2":"Phase II","graph3":"SHIRE PLC","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Nephrology","amount2New":0,"dosageForm":"Tablet, Chewable","sponsorNew":"SHIRE PLC \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"SHIRE PLC \/ Undisclosed"},{"orgOrder":0,"company":"SHIRE PLC","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Nephrology","country":"IRELAND","productType":"Miscellaneous","year":"2012","type":"Inapplicable","leadProduct":"Lanthanum Carbonate","moa":"Phosphate","graph1":"Nephrology","graph2":"Phase II","graph3":"SHIRE PLC","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Nephrology","amount2New":0,"dosageForm":"Tablet, Chewable","sponsorNew":"SHIRE PLC \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"SHIRE PLC \/ Undisclosed"},{"orgOrder":0,"company":"Bayer AG","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Undisclosed","country":"GERMANY","productType":"Miscellaneous","year":"2017","type":"Inapplicable","leadProduct":"Lanthanum Carbonate","moa":"Phosphate","graph1":"Undisclosed","graph2":"Phase I","graph3":"Bayer AG","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"","amount2New":0,"dosageForm":"Tablet, Orally Disintegrating","sponsorNew":"Bayer AG \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"Bayer AG \/ Undisclosed"},{"orgOrder":0,"company":"Salem Veterans Affairs Medical Center","sponsor":"SHIRE PLC","pharmaFlowCategory":"DU","therapeuticArea":"Nephrology","country":"U.S.A","productType":"Miscellaneous","year":"2011","type":"Inapplicable","leadProduct":"Lanthanum Carbonate","moa":"Phosphate","graph1":"Nephrology","graph2":"Phase III","graph3":"Salem Veterans Affairs Medical Center","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Nephrology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Salem Veterans Affairs Medical Center \/ SHIRE PLC","highestDevelopmentStatusID":"10","companyTruncated":"Salem Veterans Affairs Medical Center \/ SHIRE PLC"},{"orgOrder":0,"company":"University of Wisconsin, Madison","sponsor":"SHIRE PLC","pharmaFlowCategory":"DU","therapeuticArea":"Rare Diseases and Disorders","country":"U.S.A","productType":"Miscellaneous","year":"2011","type":"Inapplicable","leadProduct":"Lanthanum Carbonate","moa":"Phosphate","graph1":"Rare Diseases and Disorders","graph2":"Phase I","graph3":"University of Wisconsin, Madison","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Rare Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"University of Wisconsin, Madison \/ SHIRE PLC","highestDevelopmentStatusID":"6","companyTruncated":"University of Wisconsin, Madison \/ SHIRE PLC"},{"orgOrder":0,"company":"Unicycive Therapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Nephrology","country":"U.S.A","productType":"Miscellaneous","year":"2022","type":"Inapplicable","leadProduct":"Lanthanum Carbonate","moa":"Phosphate","graph1":"Nephrology","graph2":"Phase III","graph3":"Unicycive Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Nephrology","amount2New":0,"dosageForm":"Pill","sponsorNew":"Unicycive Therapeutics \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Unicycive Therapeutics \/ Undisclosed"},{"orgOrder":0,"company":"Spectrum Pharmaceuticals","sponsor":"Unicycive Therapeutics","pharmaFlowCategory":"D","therapeuticArea":"Nephrology","country":"U.S.A","productType":"Miscellaneous","year":"2020","type":"Acquisition","leadProduct":"Lanthanum Carbonate","moa":"Phosphate","graph1":"Nephrology","graph2":"Phase III","graph3":"Spectrum Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Nephrology","amount2New":0,"dosageForm":"Pill","sponsorNew":"Spectrum Pharmaceuticals \/ Unicycive Therapeutics","highestDevelopmentStatusID":"10","companyTruncated":"Spectrum Pharmaceuticals \/ Unicycive Therapeutics"}]

    Find Clinical Drug Pipeline Developments & Deals for Lanthanum Carbonate

    Menu

    Lanthanum Carbonate

    ACTIVE PHARMA INGREDIENTS

    DEVELOPMENTS

    FINISHED DOSAGE FORMULATIONS

    DRUG PRODUCT COMPOSITIONS

    RELATED EXCIPIENT COMPANIES

    EXCIPIENTS BY APPLICATIONS

    DIGITAL CONTENT

    GLOBAL SALES INFORMATION

    MARKET PLACE

    PATENTS & EXCLUSIVITIES

    ANALYTICAL

    PharmaCompass
    Xls
    Filters Filter
    ×
    FILTER:
    filter
    Company Name
      filter

      Year

        filter

        DEALS // DEV.

          filter

          Country

            filter
            Sponsor
              filter

              Therapeutic Area

                filter

                Study Phase

                  filter

                  Deal Type

                    filter

                    Product Type

                      filter

                      Dosage Form

                        filter

                        Lead Product

                          filter

                          Target

                            Loading...
                            refresh Filters
                            refresh Reset Filter
                            refresh Reset Filter
                            price-trend All Developments

                            Therapeutic Area by Lead Product

                            Study Phase by Lead Product

                            Company by Lead Product

                            Top Deals by Deal Size (USD bn)

                            01

                            Unicycive Therapeutics

                            U.S.A arrow
                            OTS 2025
                            Not Confirmed

                            Unicycive Therapeutics

                            U.S.A arrow
                            OTS 2025
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Lanthanum Carbonate

                            Therapeutic Area : Nephrology

                            Study Phase : Phase III

                            Sponsor : Undisclosed

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            Unicycive Achieves Primary Endpoint in Pivotal Bioequivalence Study of Renazorb

                            Details : Renazorb (Lanthanum Dioxycarbonate) is an investigational next-generation lanthanum-based phosphate binding agent utilizing proprietary nanoparticle technology. it is being developed for the treatment of hyperphosphatemia in patients with chronic kidney ...

                            Product Name : Renazorb

                            Product Type : Miscellaneous

                            Upfront Cash : Inapplicable

                            December 28, 2022

                            Lead Product(s) : Lanthanum Carbonate

                            Therapeutic Area : Nephrology

                            Highest Development Status : Phase III

                            Sponsor : Undisclosed

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            02

                            Spectrum Pharmaceuticals

                            U.S.A arrow
                            OTS 2025
                            Not Confirmed

                            Spectrum Pharmaceuticals

                            U.S.A arrow
                            OTS 2025
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Lanthanum Carbonate

                            Therapeutic Area : Nephrology

                            Study Phase : Phase III

                            Sponsor : Unicycive Therapeutics

                            Deal Size : Undisclosed

                            Deal Type : Acquisition

                            DEALS_DEV arrow-down

                            Unicycive Therapeutics Acquires Renazorb from Spectrum Pharmaceuticals for the Treatment of Hyperphosphatemia ...

                            Details : Under the terms of the asset purchase agreement, Unicycive has acquired global rights for Renazorb and all its trademark and associated patents, and Spectrum has received an equity interest in Unicycive along with milestone and royalty payments.

                            Product Name : Renazorb

                            Product Type : Miscellaneous

                            Upfront Cash : Undisclosed

                            December 14, 2020

                            Lead Product(s) : Lanthanum Carbonate

                            Therapeutic Area : Nephrology

                            Highest Development Status : Phase III

                            Sponsor : Unicycive Therapeutics

                            Deal Size : Undisclosed

                            Deal Type : Acquisition

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            03

                            Bayer AG

                            Germany arrow
                            OTS 2025
                            Not Confirmed

                            Bayer AG

                            Germany arrow
                            OTS 2025
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Lanthanum Carbonate

                            Therapeutic Area : Undisclosed

                            Study Phase : Phase I

                            Sponsor : Undisclosed

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            Bioequivalence Study of BAY 77-1931 Orally Disintegrating Tablet

                            Details : Lanthanum Carbonate is a Other Small Molecule drug candidate, which is currently being evaluated in phase I clinical studies for the treatment of undefined medical condition.

                            Product Name : Undisclosed

                            Product Type : Miscellaneous

                            Upfront Cash : Inapplicable

                            March 08, 2017

                            Lead Product(s) : Lanthanum Carbonate

                            Therapeutic Area : Undisclosed

                            Highest Development Status : Phase I

                            Sponsor : Undisclosed

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            04

                            Osaka University

                            Country arrow
                            OTS 2025
                            Not Confirmed

                            Osaka University

                            Country arrow
                            OTS 2025
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Lanthanum Carbonate

                            Therapeutic Area : Nephrology

                            Study Phase : Phase IV

                            Sponsor : Bayer AG

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            Lanthanum Versus Calcium Carbonate for Vascular Abnormalities in Patients With CKD and Hyperphosphatemia

                            Details : Lanthanum Carbonate is a Other Small Molecule drug candidate, which is currently being evaluated in phase IV clinical studies for the treatment of Renal Insufficiency, Chronic.

                            Product Name : Undisclosed

                            Product Type : Miscellaneous

                            Upfront Cash : Inapplicable

                            September 11, 2014

                            Lead Product(s) : Lanthanum Carbonate

                            Therapeutic Area : Nephrology

                            Highest Development Status : Phase IV

                            Sponsor : Bayer AG

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            05

                            SHIRE PLC

                            United Kingdom arrow
                            OTS 2025
                            Not Confirmed

                            SHIRE PLC

                            United Kingdom arrow
                            OTS 2025
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Lanthanum Carbonate

                            Therapeutic Area : Nephrology

                            Study Phase : Phase II

                            Sponsor : Undisclosed

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            A Study to Assess the Pharmacokinetics of Lanthanum Carbonate, Investigate and Compare the Efficacy, Safety an...

                            Details : Lanthanum Carbonate is a Other Small Molecule drug candidate, which is currently being evaluated in phase II clinical studies for the treatment of Renal Insufficiency, Chronic.

                            Product Name : Undisclosed

                            Product Type : Miscellaneous

                            Upfront Cash : Inapplicable

                            October 01, 2012

                            Lead Product(s) : Lanthanum Carbonate

                            Therapeutic Area : Nephrology

                            Highest Development Status : Phase II

                            Sponsor : Undisclosed

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            06

                            Bayer AG

                            Germany arrow
                            OTS 2025
                            Not Confirmed

                            Bayer AG

                            Germany arrow
                            OTS 2025
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Lanthanum Carbonate

                            Therapeutic Area : Nephrology

                            Study Phase : Phase III

                            Sponsor : Undisclosed

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            Open Study of BAY77-1931 (Lanthanum Carbonate) in Continuous Ambulatory Peritoneal Dialysis Patients

                            Details : Lanthanum Carbonate is a Other Small Molecule drug candidate, which is currently being evaluated in phase III clinical studies for the treatment of Hyperphosphatemia.

                            Product Name : Undisclosed

                            Product Type : Miscellaneous

                            Upfront Cash : Inapplicable

                            January 26, 2012

                            Lead Product(s) : Lanthanum Carbonate

                            Therapeutic Area : Nephrology

                            Highest Development Status : Phase III

                            Sponsor : Undisclosed

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            07

                            Bayer AG

                            Germany arrow
                            OTS 2025
                            Not Confirmed

                            Bayer AG

                            Germany arrow
                            OTS 2025
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Lanthanum Carbonate

                            Therapeutic Area : Nephrology

                            Study Phase : Phase III

                            Sponsor : Undisclosed

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            Phase III Double-blind Comparative Study of BAY77-1931 (Lanthanum Carbonate) With Calcium Carbonate

                            Details : Lanthanum Carbonate is a Other Small Molecule drug candidate, which is currently being evaluated in phase III clinical studies for the treatment of Hyperphosphatemia.

                            Product Name : Undisclosed

                            Product Type : Miscellaneous

                            Upfront Cash : Inapplicable

                            January 23, 2012

                            Lead Product(s) : Lanthanum Carbonate

                            Therapeutic Area : Nephrology

                            Highest Development Status : Phase III

                            Sponsor : Undisclosed

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            08

                            Salem Veterans Affairs Medical Center

                            Country arrow
                            OTS 2025
                            Not Confirmed

                            Salem Veterans Affairs Medical Center

                            Country arrow
                            OTS 2025
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Lanthanum Carbonate

                            Therapeutic Area : Nephrology

                            Study Phase : Phase III

                            Sponsor : SHIRE PLC

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            Study Comparing Effects of Lanthanum Carbonate Versus Calcium Acetate Versus Dietary Phosphorus Restriction

                            Details : Lanthanum Carbonate is a Other Small Molecule drug candidate, which is currently being evaluated in phase III clinical studies for the treatment of Renal Insufficiency, Chronic.

                            Product Name : Undisclosed

                            Product Type : Miscellaneous

                            Upfront Cash : Inapplicable

                            May 20, 2011

                            Lead Product(s) : Lanthanum Carbonate

                            Therapeutic Area : Nephrology

                            Highest Development Status : Phase III

                            Sponsor : SHIRE PLC

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            09

                            University of Wisconsin, Madison

                            Country arrow
                            OTS 2025
                            Not Confirmed

                            University of Wisconsin, Madison

                            Country arrow
                            OTS 2025
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Lanthanum Carbonate

                            Therapeutic Area : Rare Diseases and Disorders

                            Study Phase : Phase I

                            Sponsor : SHIRE PLC

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            Efficacy of Lanthanum Carbonate in Calciphylaxis

                            Details : Lanthanum Carbonate is a Other Small Molecule drug candidate, which is currently being evaluated in phase I clinical studies for the treatment of Calciphylaxis.

                            Product Name : Undisclosed

                            Product Type : Miscellaneous

                            Upfront Cash : Inapplicable

                            February 04, 2011

                            Lead Product(s) : Lanthanum Carbonate

                            Therapeutic Area : Rare Diseases and Disorders

                            Highest Development Status : Phase I

                            Sponsor : SHIRE PLC

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            10

                            Bayer AG

                            Germany arrow
                            OTS 2025
                            Not Confirmed

                            Bayer AG

                            Germany arrow
                            OTS 2025
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Lanthanum Carbonate

                            Therapeutic Area : Nephrology

                            Study Phase : Phase III

                            Sponsor : SHIRE PLC

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            Long-term Study in Chronic Kidney Disease (Extension From Study 14817)

                            Details : Fosrenol (Lanthanum Carbonate) is a Other Small Molecule drug candidate, which is currently being evaluated in phase III clinical studies for the treatment of Hyperphosphatemia.

                            Product Name : Fosrenol

                            Product Type : Miscellaneous

                            Upfront Cash : Inapplicable

                            August 24, 2010

                            Lead Product(s) : Lanthanum Carbonate

                            Therapeutic Area : Nephrology

                            Highest Development Status : Phase III

                            Sponsor : SHIRE PLC

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth